

AMENDMENTS TO THE CLAIMS

1-26. **(Canceled)**

27. **(Currently amended)** A method for reducing memory dysfunction associated with damaged hippocampal tissue in a mammal and caused by permanent or transient global ischemia, comprising administering to the mammal a morphogen comprising a conserved C-terminal seven-cysteine skeleton that is one or more of the following:
- (a) at least about 60% identical to residues 330-431 of human OP-1 (SEQ ID NO: 2);
and
 - (b) at least about 70% homologous to residues 330-431 of human OP-1 (SEQ ID NO: 2),
- thereby reducing memory dysfunction associated with damaged hippocampal tissue in the mammal.
28. **(Previously Presented)** The method of claim 27, wherein said morphogen stimulates synapse formation between hippocampal neurons.
29. **(Previously Presented)** The method of claim 28, wherein said morphogen comprises residues 30-292 of SEQ ID NO:2.
30. **(Previously Presented)** The method of claim 28, wherein said morphogen comprises residues 330-431 of SEQ ID NO:2.
31. **(Previously Presented)** The method of claim 28, wherein said morphogen comprises residues 48-292 of SEQ ID NO:2.
32. **(Previously Presented)** The method of claim 28, wherein said morphogen comprises the amino acid sequence of SEQ ID NO:2.

33. **(Canceled)**
34. **(Currently Amended)** The method of claim 28, wherein said morphogen comprises ~~residues 293-431 of SEQ ID NO:2~~ a mature form of human OP-1.
35. **(Currently Amended)** The method of claim ~~29~~ 28, wherein said morphogen comprises ~~residues 30-431 of SEQ ID NO:2~~ a mature form of human OP-1.
36. **(Previously Presented)** The method of claim 28, wherein said morphogen is a BMP-2 polypeptide.
37. **(Previously Presented)** The method of claim 28, wherein said morphogen is a BMP-5 polypeptide.
38. **(Previously Presented)** The method of claim 28, wherein said morphogen is a BMP-6 polypeptide.
- 39-42. **(Canceled)**
43. **(Previously presented)** The method of claim 27, wherein the morphogen is administered by intraventricular administration.
44. **(Previously presented)** The method of claim 27, wherein the morphogen is disposed in a biocompatible microsphere.
45. **(Canceled)**
46. **(Currently Amended)** ~~The method of claim 27,~~ A method for reducing memory

dysfunction associated with damaged hippocampal tissue in a mammal, comprising administering to the mammal a morphogen comprising a conserved C-terminal seven-cysteine skeleton that is one or more of the following:

(a) at least about 60% identical to residues 330-431 of human OP-1 (SEQ ID NO: 2);
and

(b) at least about 70% homologous to residues 330-431 of human OP-1 (SEQ ID NO: 2),
wherein the damaged hippocampal tissue is damaged by neurotoxin ~~is selected from ibotenic acid, lead, ethanol, ammonia and formaldehyde.~~

47. **(Canceled)**

48. **(Currently Amended)** ~~The method of claim 27,~~ A method for reducing memory dysfunction associated with damaged hippocampal tissue in a mammal, comprising administering to the mammal a morphogen comprising a conserved C-terminal seven-cysteine skeleton that is one or more of the following:

(a) at least about 60% identical to residues 330-431 of human OP-1 (SEQ ID NO: 2);
and

(b) at least about 70% homologous to residues 330-431 of human OP-1 (SEQ ID NO: 2),
wherein the mammal is afflicted with ~~senility~~, malnutrition, glucose metabolism disorder, or anorexia.

49-50. **(Canceled)**

51. **(New)** The method of claim 48, wherein the mammal is afflicted with malnutrition.

52. **(New)** The method of claim 48, wherein the mammal is afflicted with a glucose metabolism disorder.

53. **(New)** The method of claim 48, wherein the mammal is afflicted with anorexia.